Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose IVIG plus standard medical treatment versus standard medical treatment alone for hospitalized adults with COVID-19
2020-001696-32Phase 2Completed
- Sponsor
- Instituto Grifols
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of subcuvia in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto Grifols. Primary endpoint: Composite severe outcome through Day 29. Started May 2020; status: completed.
02
Drugs
subcuvia
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001696-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001696-32.